NCT00479440View on ClinicalTrials.gov

Study Evaluating the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of SAM-315 in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

August 31, 2006

Study Completion Date

March 31, 2007

Conditions
Alzheimer Disease
Interventions
DRUG

SAM-315

All Listed Sponsors
lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00479440 - Study Evaluating the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of SAM-315 in Healthy Adults | Biotech Hunter | Biotech Hunter